Legend Biotech Corp ADR (NASDAQ:LEGN) does about 1.49M shares in volume on a normal day but saw 1978095 shares change hands in the recent trading day. The company now has a market cap of 5.29B USD. Its current market price is $28.76, marking a decrease of -0.52% compared to the previous close of $28.91. The 52 week high reached by this stock is $60.87 whilst the lowest price level in 52 weeks is $27.34. The script in recent trading has seen the stock touch a high of $75 and a low of $75.
11 analysts observing the Legend Biotech Corp ADR (LEGN) stock have set the 12-month price targets for the company’s shares at between $75 and $75. The consensus objective for the share price is $76.32, suggesting that the stock has a potential upside of 62.32% over the period. The median price target is 61.65% away from the current levels at $75.
FactSet Research has provided data showing that 11 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 11 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 08, 2024 when Redburn Atlantic initiated the stock to “Buy” and issued a price target of $86. H.C. Wainwright reiterated its price target at $86-$73.
The current price level is -6.85%, -12.26%, and -28.15% away from its SMA20, SMA50, and SMA200 respectively, with the LEGN price moving above the 50-day SMA on current market day. Legend Biotech Corp ADR (LEGN) stock is down -1.20% over the week and -16.10% over the past month. Its price is -11.62% year-to-date and -32.49% over the past year.
Its 12-month price target is $75. To reach the target analysts have set, the stock logically needs to grow 62.32 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $75, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $75.
Outstanding shares total 184.03M with insiders holding 1.33% of the shares and institutional holders owning 47.77% of the company’s common stock. The company has a return on investment of -15.86% and return on equity of -20.00%. The forward price to earnings ratio is 47.79. The beta has a value of 0.16. Price to book ratio is 5.20 and price to sales ratio is 7.27.
